| Multinational Survey-Based Chart Review Study in International Markets to Evaluate the Effectiveness, Safety, and Treatment Patterns of DUPIXENT® (Dupilumab) in Patients with Moderate-to-Severe Atopic Dermatitis |
Completed |
DUPIXENT® (Dupilumab) |
4 |
DUT0012 |
Specialized Medical Center (Riyadh),Dr. Erfan & Bagedo General Hospital (Jeddah) |
| Nucala Effectiveness Study (NEST) in Emerging Markets |
Completed |
Mepolizumab |
3 |
213475 |
King Fahad University Hospital (Al-Khobar) |
| A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice |
Ongoing |
Sogroya® |
4 |
NN8640-451 |
My Clinic (Jeddah) |
| A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study |
Terminated |
ST5040 (2,2-dimethylbutanoic acid) |
4 |
HST20-CL01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients A Prospective, Multi-Centre, Double-Blind, Randomized, Controlled Trial. SPICE IV |
Ongoing |
DEXMEDETOMIDINE |
4 |
SCT21R/006/04 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| Vitamin C as a potential ameliorating agent against hepatotoxicity among alcoholic abusers |
Completed |
Vitamin C (ascorbic acid ) Cevital |
3 |
20111803 |
Mental Health Hospital (Abha) |
| A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study. |
Terminated |
ribociclib |
2 |
CLEE011A3201C |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER |
Completed |
ATEZOLIZUMAB / PACLITAXEL |
3 |
MO39196 |
IMC (Closed), KFSH (Closed), KFMC (Closed) |
| AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT |
Completed |
Atezolizumab (MPDL3280A; RO5541267) |
3 |
MO29983 |
KFSH & RC-R |
| Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Ongoing |
WARFARIN SODIUM |
3 |
2231351 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
